Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Researchers have created an artificial intelligence system for predicting, not simply tracking, potential side effects from drug combinations.
Scientists have discovered a “big bang” of Alzheimer’s disease — the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects.
People living in England will be the first in the world to have access to DNA tests as routine care starting this fall, putting the NHS at the forefront of healthcare, as it takes a huge step towards precision medicine.
There’s no therapy developed yet, that can stop cancer cells from moving throughout the body. New research shows that it may be possible to do so, in freezing cancer cells and killing them where they stand.
To understand the biology of diseased organs, researchers can use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types.
The Swiss drugmaker has clearly noticed the genomic profiling group’s ability to personalise cancer care, now that it will take complete ownership of the company.
Microbiotica has entered into a multi-year strategic collaboration with Genentech, a Roche company, to discover, develop, and commercialise biomarkers, targets, and medicines for inflammatory bowel disease.
A new study provides a unique look at a novel strategy — clinical trials in a dish — that bridges preclinical testing and clinical trials.
New findings suggest that a person’s own immune system helps nudge him or her down the path toward Parkinson’s, and that restraining the immune system with drugs potentially could prevent the neurological disorder.